Feasibility and acceptability of using bronchial hyperresponsiveness to manage asthma in primary care: a pilot study

*James A Turton*, Nicholas J Glasgow, John D Brannan

* Medical School, Australian National University, Canberra, ACT 2606, Australia
b Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia

Original submission 15th November 2010; resubmitted 31st March 2011; revised 21st June 2011; accepted 2nd August 2011

Abstract

**Aims:** To determine if indirect testing for bronchial hyperresponsiveness (BHR) to monitor inhaled corticosteroid (ICS) treatment in asthma is feasible and acceptable in primary care.

**Methods:** Fourteen adult patients with asthma aged 22–70 years (4M:10F, forced expiratory volume in 1 s >70% predicted) taking ICS performed a test for BHR using mannitol on three visits 6 weeks apart. ICS dose adjustments were made based on the presence of BHR. The Asthma Quality of Life Questionnaire (AQLQ) and the Asthma Control Questionnaire were used at each visit. A semi structured interview at study exit assessed subject acceptability.

**Results:** BHR did not return in those with no BHR at study entry (n=9) with decreasing ICS dose. Improvements in BHR with increasing ICS dose (n=5) were observed with clinically significant improvements in AQLQ (mean score increase >0.5, p=0.02). Feasibility and acceptability of BHR testing was demonstrated.

**Conclusions:** It is feasible and acceptable to perform BHR testing using mannitol to help identify patients with asthma who would benefit from ICS dose increases and those with no BHR who could have a dose reduction.

**Trial Registration:** Australia New Zealand Clinical Trial Registry ACTRN12610000807055

© 2011 Primary Care Respiratory Society UK. All rights reserved.

JA Turton et al. Prim Care Respir J 2011; 20(x): xxx-xxx

http://dx.doi.org/10.4104/pcrj.2011.00079

Keywords asthma control, bronchial hyperresponsiveness, inhaled corticosteroids, treatment, mannitol, primary care

Introduction

Asthma is a chronic inflammatory disease that is commonly managed in primary care clinics. Asthma symptoms and lung function are not always effective at predicting the benefits of inhaled corticosteroids (ICS), and this may explain the significant morbidity seen in the presence of management guidelines. All clinicians are currently faced with the challenge of determining asthma severity and control without an accepted reliable indicator of treatment effectiveness. There have been calls for changes in asthma management and suggestions of systematic monitoring of disease activity using objective patient-orientated measures. Considering that there are no new asthma treatments in the pipeline that are superior to ICS, more effective ways of using ICS in primary care are now needed.

The two key pathophysiological features of asthma are bronchial hyperresponsiveness (BHR) and inflammation. These often persist beyond initial improvements in symptoms and lung function. Tests for BHR have had practical limitations in primary care; however, a safe and effective point-of-care test using inhaled mannitol is now available. BHR to mannitol results from the release of endogenous mediators (e.g. histamine, leukotrienes, prostaglandins) from resident inflammatory cells that are sensitive to ICS such as mast cells and eosinophils. Mannitol provocation testing has demonstrated potential in monitoring both the introduction and withdrawal of ICS.

We performed a pilot study in primary care to assess the
feasibility and acceptability of using inhaled mannitol to manage asthma with ICS. We also wanted to explore whether measuring BHR could help with making decisions on reducing or increasing ICS dose in a primary care population of asthma patients.

Methods

Subjects

Subjects were recruited from a primary care practice in Canberra, Australia over a 30-week period in 2008–2009. An invitation was mailed to all adults attending the practice aged 18–70 years with a clinical diagnosis of asthma who had been prescribed any form of ICS within the previous year. Subjects were excluded if there was a diagnosis of any other lung disease or if they had been unwell in the 4 weeks prior to joining the study. Ex-smokers with a <10 pack-year history and no smoking in the previous 6 months were eligible; current smokers were excluded. Subjects were required to have a forced expiratory volume in 1 second (FEV1) of >70% predicted.

Study design

The study used an open single-arm prospective observational design. Eligible subjects had a mannitol challenge test performed at baseline. The decision to increase, decrease, or maintain ICS or long-acting β2-agonist (LABA) according to the presence of BHR was made by the primary care physician. If BHR was present, the dose of ICS was increased. If there was no BHR, the dose of ICS was decreased. Subjects with no BHR taking combination ICS and LABA with normal lung function had their LABA replaced with a short-acting β2-agonist (SABA) as required. They were invited to state a goal for their asthma treatment and were encouraged to be adherent to twice daily dosing with ICS in order to achieve this goal. Subjects returned to the primary care practice for two further visits each 6 weeks apart for repeat mannitol challenge testing and ICS dose adjustment. They were able to return for an unscheduled visit at any time in the 12 weeks of the study if they experienced an exacerbation of respiratory symptoms. All visits were performed by a primary care physician (lead author) trained in spirometry and bronchial provocation challenge testing.

Spirometry

Spirometry was performed at all visits according to the American Thoracic Society criteria using NHANES III predicted values17 on a MicroLab™ ML3500 spirometer (Micromedical, UK) which underwent a daily calibration check with a 3L syringe.

Mannitol challenge

Inhaled mannitol was delivered using a commercial preparation (Aridol™, Pharmaxis Ltd, Frenchs Forest, NSW, Australia) which currently has regulatory approval in the USA, the European Union, South Korea and Australia for the assessment of BHR to assist in asthma diagnosis. Prior to testing, subjects were asked to withhold SABA for 8 hrs, ICS for 12 hrs and ICS/LABA combinations for 24 hrs. Increasing doses of mannitol (0, 5, 10, 20, 40, 80, 160, 160, 160mg) were inhaled via a dry powder inhaler until either a total cumulative dose of 635mg was administered or a 15% fall in FEV1 from baseline was observed 60 s after dosing.18 Airway sensitivity is expressed as the cumulative provoking dose of mannitol to cause a 15% fall in FEV1 (PD15).

All visits took place in a standard primary care clinical consultation room and required no more facilities than a portable spirometer, salbutamol (pressurised metered dose inhaler (pMDI) and spacer), a stopwatch and a hand calculator. Oxygen and the facilities to administer nebulised inhaled β2-agonist were located in an adjacent room of the practice.

Inhaled corticosteroid adherence monitoring

Subjects taking ICS using pMDIs were issued with the Smartinhaler™ monitoring device (Nexus6 Ltd, Auckland, New Zealand). The Smartinhaler™ recorded the time and date of each pMDI actuation. There was no covert monitoring as subjects were fully informed of the nature of this device. Those subjects taking ICS via a dry powder inhaler could not be monitored for adherence using the Smartinhaler™ device.

Questionnaires

The Asthma Quality of Life Questionnaire (AQLQ)18 and the Asthma Control Questionnaire (ACQ)19,20 were administered at each visit. An additional questionnaire to assess acceptability of the mannitol challenge test was also used. Subjects were asked to rank on a score of 1–5 (with 5 the most favourable score) how rapid and easy the test was, how safe and comfortable they felt during the procedure, and if they would perform the test again. Each subject participated in a semi structured interview at the final visit and was asked the following three questions by the investigator:

1. “What do you feel about having your asthma monitored using this process?”
2. “How do you think that having a personalised goal for your treatment has improved your asthma?”
3. “Do you think that the Smartinhaler™ device had any impact on your asthma management?”

The responses were hand recorded and analysed for themes.

Statistics

The provoking dose of mannitol (PD15) is calculated from the linear interpolation of the dose (mg) response (% fall in FEV1) curve. If no sensitivity to mannitol was recorded, this was assigned a PD15 of 680mg for statistical purposes. Where possible, Student paired t-tests were performed on normally distributed data. Unless otherwise stated, data are expressed as mean ± standard deviation (SD).

Ethics

Ethical approval was obtained from the Human Research Ethics Committees of the Australian National University (2008/497) and Australian Capital Territory Health (ETH.8/08.759). All subjects gave informed consent prior to participation in the study.
Results

One hundred and forty-seven patients were identified from the primary care clinic’s electronic database. Twenty-seven (18%) responded with 21 (14%) meeting the study eligibility criteria. Of the 21 screened subjects, seven (33.3%) were ineligible due to abnormal spirometry with a mean FEV₁ 58% (range 40–69%) of the predicted value. The baseline demographic characteristics of the subjects are summarised in Table 1.

The acceptability of the challenge procedure was high with the pooled median responses for speed, ease, safety,

### Table 1. Demographics

<table>
<thead>
<tr>
<th>Subject No.</th>
<th>Age (yrs)</th>
<th>Sex</th>
<th>BMI (kg/m²)</th>
<th>Age of diagnosis</th>
<th>GINA class Pred</th>
<th>Baseline FEV₁%</th>
<th>Baseline FEV₁/FVC</th>
<th>Asthma medication (µg/day)</th>
<th>Inhaled dose (mg)</th>
<th>Mannitol PD₁₅</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>38</td>
<td>F</td>
<td>22.6</td>
<td>20</td>
<td>3</td>
<td>86.0</td>
<td>86.3</td>
<td>FLU/Sm</td>
<td>1000/200</td>
<td>265</td>
</tr>
<tr>
<td>2</td>
<td>48</td>
<td>F</td>
<td>22.8</td>
<td>20</td>
<td>1</td>
<td>83.9</td>
<td>76.0</td>
<td>FLU/Sm</td>
<td>500/100</td>
<td>458</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
<td>F</td>
<td>19.5</td>
<td>58</td>
<td>2</td>
<td>71.9</td>
<td>77.8</td>
<td>BUD/Ef</td>
<td>200/6</td>
<td>No PD₁₅</td>
</tr>
<tr>
<td>4</td>
<td>45</td>
<td>M</td>
<td>28.0</td>
<td>44</td>
<td>1</td>
<td>118.4</td>
<td>85.5</td>
<td>BUD/Ef</td>
<td>800/24</td>
<td>No PD₁₅</td>
</tr>
<tr>
<td>5</td>
<td>70</td>
<td>F</td>
<td>29.9</td>
<td>68</td>
<td>3</td>
<td>71.5</td>
<td>75.7</td>
<td>BUD/Ef</td>
<td>800/24</td>
<td>No PD₁₅</td>
</tr>
<tr>
<td>6</td>
<td>22</td>
<td>F</td>
<td>26.2</td>
<td>4</td>
<td>2</td>
<td>97.9</td>
<td>82.4</td>
<td>FLU/Sm</td>
<td>1000/100</td>
<td>No PD₁₅</td>
</tr>
<tr>
<td>7</td>
<td>69</td>
<td>M</td>
<td>32.7</td>
<td>55</td>
<td>3</td>
<td>71.5</td>
<td>68.1</td>
<td>BUD/Ef</td>
<td>400/12</td>
<td>No PD₁₅</td>
</tr>
<tr>
<td>8</td>
<td>36</td>
<td>F</td>
<td>26.9</td>
<td>34</td>
<td>2</td>
<td>90.1</td>
<td>84.0</td>
<td>BUD</td>
<td>400</td>
<td>No PD₁₅</td>
</tr>
<tr>
<td>9</td>
<td>55</td>
<td>M</td>
<td>29.0</td>
<td>30</td>
<td>2</td>
<td>79.9</td>
<td>68.9</td>
<td>FLU</td>
<td>500</td>
<td>47</td>
</tr>
<tr>
<td>10</td>
<td>64</td>
<td>F</td>
<td>24.9</td>
<td>53</td>
<td>2</td>
<td>95.3</td>
<td>83.6</td>
<td>BUD/Ef</td>
<td>800/24</td>
<td>No PD₁₅</td>
</tr>
<tr>
<td>11</td>
<td>62</td>
<td>F</td>
<td>36.0</td>
<td>42</td>
<td>2</td>
<td>83.7</td>
<td>86.6</td>
<td>BUD/Ef</td>
<td>800/24</td>
<td>No PD₁₅</td>
</tr>
<tr>
<td>12</td>
<td>62</td>
<td>F</td>
<td>23.6</td>
<td>33</td>
<td>2</td>
<td>79.9</td>
<td>72.9</td>
<td>BUD/Ef</td>
<td>400/12</td>
<td>No PD₁₅</td>
</tr>
<tr>
<td>13</td>
<td>40</td>
<td>M</td>
<td>20.2</td>
<td>5</td>
<td>2</td>
<td>93.7</td>
<td>73.4</td>
<td>FLU/Sm</td>
<td>500/50</td>
<td>544</td>
</tr>
<tr>
<td>14</td>
<td>60</td>
<td>F</td>
<td>25.9</td>
<td>59</td>
<td>1</td>
<td>97.1</td>
<td>88.7</td>
<td>BUD</td>
<td>100</td>
<td>No PD₁₅</td>
</tr>
<tr>
<td>Mean</td>
<td>55</td>
<td>F/M</td>
<td>26.3</td>
<td>37.5</td>
<td>4</td>
<td>87.2</td>
<td>79.4</td>
<td>259.7**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>22-70</td>
<td></td>
<td>19.5-36</td>
<td>4-68</td>
<td></td>
<td>71.5-118.4</td>
<td>68.1-89.7</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BEC=beclomethasone; BUD=budesonide; Ef=eformoterol; FL=fluticasone; F=female; M=male; S=salbutamol; Sm=salmeterol; / denotes in combination
No PD₁₅ = a 15% fall in FEV₁ to mannitol (PD₁₅) not observed.
*Ex-smoker. **Geometric mean for those with a PD₁₅.

### Table 2. Qualitative analysis of semi structured interview at study exit

<table>
<thead>
<tr>
<th>Theme</th>
<th>Exemplar</th>
</tr>
</thead>
<tbody>
<tr>
<td>What do you feel about having your asthma monitored using this process?</td>
<td>&quot;When well previously I thought (my asthma) was cured – now I know I should be taking (ICS) all the time&quot;</td>
</tr>
<tr>
<td>Chronic disease insight</td>
<td>&quot;(the process) helps measure (the) effect of medication&quot;</td>
</tr>
<tr>
<td>Objective nature of the management process</td>
<td>&quot;(ICS) dose adjustments make sense&quot;</td>
</tr>
<tr>
<td>Comparison with usual standard of asthma care</td>
<td>&quot;Follow-up using measurement was better&quot;</td>
</tr>
<tr>
<td>How do you think that having a personalised goal for your treatment has improved your asthma?*</td>
<td>&quot;Better process than just seeing the doctor for 10 minutes&quot;</td>
</tr>
<tr>
<td>Therapeutic alliance</td>
<td>&quot;(a) goal focuses (my) efforts&quot;</td>
</tr>
<tr>
<td>Insight</td>
<td>&quot;(in the past) I treated symptoms without (a) long term view&quot;</td>
</tr>
<tr>
<td>Do you think that the Smartinhaler™ device had any impact on your asthma management?</td>
<td>&quot;Knowing that it was recording dosing time made me more conscious of taking (my) medicine&quot;</td>
</tr>
</tbody>
</table>

*Responses from BHR positive subjects only.
comfort, and overall rating being scored 4 out of 5 for all visits. All subjects indicated that they would be prepared to undertake a mannitol challenge at a future time if needed. The qualitative analysis of the semi structured interview shows the subjects’ views of asthma monitoring, goal setting, and electronic adherence monitoring of ICS use (Table 2).

All subjects performed spirometry and the mannitol challenge test per protocol. No subject withdrew from the study. There were no serious adverse events and all of those reported were minor. Only one subject had an unscheduled visit for increased respiratory symptoms that resolved rapidly (Table 1, subject 7). The mean time of the challenge tests was 19 min (range 9–24).

Of the 14 enrolled subjects who proceeded to a mannitol challenge at the first visit, nine had no BHR while five demonstrated BHR (Table 1 and Figure 1). All subjects with no BHR at the initial visit maintained no BHR throughout the study despite a significant decrease in ICS dose and withdrawal of LABA (Figure 2). This dose reduction resulted in no significant changes in mean AQLQ and ACQ scores (Figure 1). Three subjects in the no BHR group had ACQ scores in the inadequately controlled asthma range at week 12. For these subjects the percentage fall in FEV\(_1\) (after a cumulative mannitol dose of 635mg) was 0%, 3.5% and 6.4%, respectively. Four subjects with mild BHR to mannitol (PD\(_{15}\)
Table 3. Adherence to inhaled corticosteroids by electronic dose monitoring

<table>
<thead>
<tr>
<th>Subject no.</th>
<th>Baseline BHR</th>
<th>Average measured adherence (%) 0–6 weeks</th>
<th>6–12 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>BHR</td>
<td>99</td>
<td>100</td>
</tr>
<tr>
<td>2</td>
<td>BHR</td>
<td>(DF)*</td>
<td>82</td>
</tr>
<tr>
<td>5</td>
<td>No BHR</td>
<td>(DPI)*</td>
<td>45</td>
</tr>
<tr>
<td>6</td>
<td>No BHR</td>
<td>100</td>
<td>(DF)*</td>
</tr>
<tr>
<td>8</td>
<td>No BHR</td>
<td>88</td>
<td>(ICS withdrawn)*</td>
</tr>
<tr>
<td>9</td>
<td>BHR</td>
<td>82</td>
<td>93</td>
</tr>
<tr>
<td>10</td>
<td>BHR</td>
<td>(DPI)*</td>
<td>95</td>
</tr>
<tr>
<td>11</td>
<td>No BHR</td>
<td>68</td>
<td>32</td>
</tr>
<tr>
<td>12</td>
<td>No BHR</td>
<td>93</td>
<td>96</td>
</tr>
<tr>
<td>13</td>
<td>BHR</td>
<td>91</td>
<td>92</td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td>89</td>
<td>79</td>
</tr>
<tr>
<td>SD</td>
<td></td>
<td>11</td>
<td>26</td>
</tr>
</tbody>
</table>

*Adherence data not collected (reason stated).
BHR=bronchial hyperresponsiveness; DF=device failure; DPI=dry powder inhaler (unable to use Smartinhaler™); ICS=inhaled corticosteroid.

>155mg) had no BHR following a significant increase in ICS dose after 6 weeks (Figure 1). The subject with the most severe BHR (Table 1, subject 9, PD15=47mg) improved over 12 weeks to the mild range. The reduction in PD15 in the BHR baseline positive group was statistically significant (p<0.05) at 6 and 12 weeks (Figure 1). This corresponded with a statistically significant improvement in both AQLQ and ACQ over 12 weeks (Figure 1). There was also a clinically significant improvement (>0.5 increase in mean score) in the overall AQLQ scores as well as in the symptoms and activity limitation domains. There were no significant changes in the mean FEV1 from baseline to week 12 in those who had BHR or no BHR (Figure 1).

Adherence to ICS therapy was observed to be an average of 84% (range 45–100%) for the 12 weeks of the study in the subgroup of subjects using a pMDI (n=10) (Table 3). Those with BHR at baseline (n=5) were observed to maintain a high degree of adherence over 6–12 weeks (92%, range 82–100%). Monitoring data for two subjects were lost due to data upload failures of the Smartinhaler™ device (subjects 2 and 6). One subject (subject 8) had adherence data for ICS use in the first 6-week treatment period but not for the second 6-week treatment period as ICS was withdrawn.

Discussion

This study demonstrated that BHR testing using inhaled mannitol was feasible and acceptable in the primary care setting. This supports the findings of two large phase 3 studies10,11 that demonstrated safety and efficacy of the mannitol challenge in tertiary care. Furthermore, despite the small numbers, we identified clinically significant improvements in AQLQ associated with ‘well controlled’ ACQ scores. These changes correlated with improvements in BHR after ICS dose increases. The AQLQ is validated to measure the effect of asthma therapies on symptoms, and other studies have needed much larger numbers of subjects to show such improvement.21 This finding is consistent with studies that have shown clinical improvements with ICS over weeks to months in association with reductions in BHR to mannitol.14,15 This finding supports a hypothesis that no response to mannitol may be a marker of asthma control.15,16 We also successfully reduced ICS in subjects with no BHR with no deterioration in AQLQ scores in the majority of subjects, and no change in lung function.

We were able to perform challenge testing using the resources that are commonly found in primary care clinics. The time to perform the mannitol challenge test in this pilot study was in keeping with the times observed in tertiary care settings.10,11 The study clinician performed all the spirometry and challenge tests throughout this pilot study, in contrast to the likely normal practice in primary care clinics. We do not anticipate that busy primary care clinicians would perform these measurements themselves but foresee that primary care nurses, physician assistants or respiratory therapists might embrace such a role. Mannitol challenge testing by allied health staff may thus be integrated into a platform of asthma education.

A qualitative analysis of the semi structured interviews at the final visit found themes of an increased understanding of the chronic nature of asthma and an understanding of the value of objectively measuring asthma control. Subjects considered that this monitoring process was better than past experiences of primary care asthma management. Personalised asthma treatment goals were valued, as was the process of goal setting between doctor and patient. We restricted the thematic analysis related to goal setting to those subjects who were BHR positive at study entry as these were the ones who had an objective improvement in their asthma. Future studies should address the issue of goal setting for all subjects (BHR positive and negative) in an open-ended manner. We propose that this process of BHR monitoring has the capacity to both raise and meet the expectations for better primary care asthma management in both clinicians and patients.

While the subject retention in this pilot study was high, we would like to have recruited more patients with asthma overall. The low response rate to mailed invitations (18%) was disappointing although not uncommon in primary care research.23 We feel that our study is representative of the usual way in which primary care clinics recall patients for treatment. However, despite the small numbers, the results of this pilot study are in agreement with studies in larger populations.14,16 A cause for concern is that one-third of screened subjects had poor lung function (FEV1 <70%) and failed to meet the eligibility criteria for BHR testing. This observation is supported by studies in primary care showing that many subjects have poor asthma...
control, and highlights the need for spirometry testing in chronic respiratory disease as an urgent continuing priority. For patients with asthma with poor lung function, it is possible that they may be eligible for BHR monitoring once lung function has improved with ICS therapy.

Primary care asthma populations are a heterogeneous group of patients with predominantly mild to moderate asthma. Overdiagnosis of asthma in primary care may be up to 30%,24 and in this pilot study we may have attracted subjects wanting confirmation of their diagnosis. We did observe that some subjects had increases in AQLQ and ACQ severity scores in the presence of ICS withdrawal with no BHR. These subjects showed percentage falls in FEV1 that are comparable to non-asthma patients without airway reactivity.10 Such subjects may require further clinical investigation. Using this study design we were able to select out subjects who would benefit from an increase in ICS dose and also identified subjects in whom a decrease in dose could be made. The absence of BHR to stimuli such as mannitol or exercise in asthma patients who take ICS suggests that the optimal dose of ICS has been reached.11,12 We were able to withdraw LABA in patients both with and without BHR at 12 weeks. Larger studies are warranted to determine if LABA can be removed in subjects who are otherwise well controlled and have no BHR.

It has been shown that primary care clinicians are less likely to decrease the dose of ICS than their counterparts in tertiary care.25 This may be because asthma symptoms and lung function are the only readily accessible markers of disease activity in primary care. In this pilot study, symptoms and lung function at baseline would not have been sufficient on their own to make a decision on down-titrating ICS doses or withdrawing LABA.

This study featured an electronic dose adherence monitor for pMDI-delivered ICS. Adherence to ICS is often poor (50%) and is related to poor asthma outcomes.26 In contrast, we observed high levels of sustained adherence (>80%) to 12 weeks, predominantly in those whom we identified as having BHR. This finding may be due to a combination of the awareness of the dose monitors as well as the process of goal setting and encouragement by the study clinician. We did not measure adherence during a run in period and future studies may address this issue.

Conclusions
We have demonstrated that it is feasible to perform a test for BHR in primary care. The test was safe and acceptable. Monitoring asthma using this test has the potential to improve asthma control as well as lowering ICS doses. While the subject numbers were small, clinically meaningful outcomes were observed based on titrating ICS dose according to BHR. Larger studies in primary care are now warranted.

Acknowledgements
The authors wish to acknowledge the support of Professor Marjan Klaic and the Primary Health Care Research, Evaluation and Development (PCHRED) program at the Australian National University in ensuring that this study could be completed successfully. They would like to thank Professor Juniper for her permission to use the AQLQ and ACQ questionnaires. Pharmaxis Ltd provided Aridol™ test kits and the temporary loan of a spirometer. GSK Ltd provided some Ventolin™ inhalers and Volumatic™ spacer devices to support the study. Neither Pharmaxis Ltd nor GSK Ltd were involved in the study design, collection, interpretation of data, or production of this paper.

Conflicts of interest
JAT holds shares in Pharmaxis Ltd. NJG has no conflict of interest. JDB receives royalties from the sale of Aridol™/Osmohale™, holds shares in Pharmaxis Ltd, and has acted as a consultant to Pharmaxis Ltd.

Contributors
JAT and JDB have access to the data and take responsibility for the integrity of the data and accuracy of the data analysis. JAT contributed to the design, implementation, interpretation, analysis and writing. JDB contributed to the design, interpretation, analysis and writing. NJG contributed to the design, interpretation and writing.

Funding
An Australian General Practice Education & Training (GPET) Registrar Research Fund Grant supported this work.

References

AHEAD OF PRINT - ARTICLE IN PRESS
with hypertonic (4.5%) saline. Respir Res 2005;6:144.


